Brief: Cartesian Therapeutics Highlights Recent Progress And Outlines 2026 Outlook
09/01/2026 13:34
Jan 9 (Reuters) - Cartesian Therapeutics Inc RNAC.O: CARTESIAN THERAPEUTICS HIGHLIGHTS RECENT PROGRESS AND OUTLINES 2026 OUTLOOK CARTESIAN THERAPEUTICS INC - ENROLLMENT ON TRACK IN PHASE 3 AURORA TRIAL FOR DESCARTES-08 CARTESIAN THERAPEUTICS INC - FDA ACCEPTS IND APPLICATION FOR DESCARTES-08 IN MYOSITIS CARTESIAN THERAPEUTICS INC - PHASE 1/2 PEDIATRIC TRIAL FOR DESCARTES-08 INITIATED Source text: ID:nGNX4dQZlq Further company coverage: RNAC.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cartesian Therapeutics
See all newsBrief: Cartesian Therapeutics Announces Additional Retreatment Data For Descartes-08 Highlighting Deep And Durable Responses In Patients With Myasthenia Gravis
Cartesian Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cartesian Therapeutics Q2 net income steady
Brief: Cartesian Therapeutics Inc Q2 Net Income USD 15.769 Million
Cartesian Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview